Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study

Authors

Katia Alves (ORCID: https://orcid.org/0000-0002-4181-2051)
Fernando Noriega (ORCID: https://orcid.org/0000-0001-5133-3559)
Joyce S. Plested (ORCID: https://orcid.org/0009-0007-0283-0779)
Raburn M. Mallory (ORCID: https://orcid.org/0000-0002-2563-9981)
Katherine Clegg Smith (ORCID: https://orcid.org/0000-0003-2140-1690)
Raj Kalkeri (ORCID: https://orcid.org/0000-0002-1188-277X)
Mamadou Kaba
Zhaohui Cai (ORCID: https://orcid.org/0000-0001-5935-3570)
Mingzhu Zhu (ORCID: https://orcid.org/0009-0005-1628-7442)
Shane Cloney‐Clark
Alex Kouassi
J C Nelson

Institutions

Novavax (United States) (US)

Publication Details

Journal: Vaccine
Published: 2025-04-04
DOI: https://doi.org/10.1016/j.vaccine.2025.127046
Citations: 3
Primary Topic: SARS-CoV-2 and COVID-19 Research
Type: article
Field-Weighted Citation Impact: 4.19

Funders

Novavax

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study

Katia Alves, Fernando Noriega, Joyce S. Plested, Raburn M. Mallory et al.

Apr 4, 2025

3 citations

Vaccine

SARS-CoV-2 and COVID-19 Research

4.19

article

Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study

Katia Alves, Fernando Noriega, Joyce S. Plested, Raburn M. Mallory, Katherine Clegg Smith, Raj Kalkeri, Mamadou Kaba, Zhaohui Cai, Mingzhu Zhu, Shane Cloney‐Clark, Alex Kouassi, J C Nelson

April 4, 2025article en

3 citations

Abstract

No abstract available for this paper.

VaccineVol. 55

Novavax (United States) (US)

Novavax

Good health and well-being

Openalex Percentile: Top 7%

SARS-CoV-2 and COVID-19 Research

4.19

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.